RecruitingHematological Malignancies
A Study of Talquetamab in Participants With Relapsed or Refractory Multiple Myeloma
Eligible age
18+ yrs
Accepts
All genders
Locations
12 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The purpose of this study is to evaluate the efficacy and safety of talquetamab in participants with relapsed or refractory multiple myeloma at the recommended Phase 2 dose(s) (RP2Ds) (Part 3).
Sponsor: Janssen Research & Development, LLC
You may qualify if…
- ✓ Documented initial diagnosis of multiple myeloma according to international myeloma working group (IMWG) diagnostic criteria
- ✓ Part 3: Measurable disease cohort A, cohort B, cohort C and cohort D: multiple myeloma must be measurable by central laboratory assessment; Cohort E: Multiple myeloma must be measurable by local laboratory assessment
- ✓ Eastern Cooperative Oncology Group (ECOG) performance status score of 0 to 2
- ✓ Women of childbearing potential must have a negative pregnancy test at screening and prior to the first dose of study drug using a highly sensitive pregnancy test either serum (beta human chorionic gonadotropin \[hCG\]) or urine
- ✓ Willing and able to adhere to the prohibitions and restrictions specified in this protocol
You may not qualify if…
- ✕ Part 3 only: Cohort A and Cohort C only: exposed to a CAR-T or T cell redirection therapy at any time. Cohort B, Cohort D and Cohort E: T cell redirection therapy within 3 months
- ✕ Toxicities from previous anticancer therapies should have resolved to baseline levels or to Grade 1 or less except for alopecia or peripheral neuropathy
- ✕ Received a cumulative dose of corticosteroids equivalent to \>= 140 milligram (mg) of prednisone within the 14-day period before the first dose of study drug (does not include pretreatment medication)
- ✕ Stroke or seizure within 6 months prior to signing the informed consent form (ICF)
Where it's recruiting
Source: ClinicalTrials.gov · NCT04634552 · last updated 2026-11-03